The objective of this study was to undertake a postmarketing safety surveillance study of losartan, the first specific angiotensin-II receptor antagonist to be marketed in England. It is a non-interventional observational cohort study using the technique of prescription-event monitoring. Subjects who took part in the study were from 14 522 patients treated by general practitioners in England. We recorded adverse drug reactions, adverse events, reasons for stopping the drug, pregnancies and deaths. The results were that general practitioners considered the drug to have been effective in 85.9% of the
Introduction
The safety of new antihypertensive agents is of especial importance because they are likely to be used for the long-term treatment of very considerable numbers of patients. The median number of subjects forming the safety database for successful product licenses for drugs containing new active substances is only 1528 volunteers and patients. 1 This is small compared with the number of patients likely to receive a new drug for a common condition such as hypertension. In the case of losartan the original application for marketing approval contained safety data on approximately 3500 patients, of whom some 300 had been treated with the drug for 1 year (Linda Burton Gidman, personal communication). However, the pre-marketing database is likely be non-representative of the age and type of patients prescribed a new blood pressurelowering drug once it enters everyday clinical usage. For these reasons safety depends upon post-marketing surveillance-and this paper reports such a study in over 14 000 patients prescribed losartan in the period immediately following the launch of that drug in the UK. This study represents an exercise in pharmacovigilance which, in the European Community, has its legal basis in Directives 65/65, 75/319 and in Regulation 2309/93.
Losartan potassium is available in tablets of 50 and 25 mg. The starting and maintenance dose is 50 patients evaluated for effectiveness. Dizziness, malaise, lassitude, nausea, cough and headache were among the most frequently reported adverse drug reactions, reasons for stopping the drug and events of highest incidence density. None of the deaths that occurred were attributed to losartan and no serious unexpected adverse reactions or interactions were identified. In conclusion losartan has an acceptable safety profile and the study confirms the safety information given in the current Summary of Product characteristics for losartan. mg once daily for most patients although a lower starting dose is recommended in patients over 75 years of age and in certain other groups including patients with moderate to severe renal impairment. The drug is a specific angiotensin-II receptor antagonist and, like other drugs which act directly on the renin-angiotensin-aldosterone system, is contraindicated in pregnancy. 2 Losartan is the first of the angiotensin-II blockers to be marketed in the UK.
Theoretically it offers advantages of increased selectivity, specificity and maintained blockade of the circulating and tissue renin-angiotensin system at the AT1 receptor without the adverse reactions associated with angiotensin-converting enzyme (ACE) inhibitors.
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Subjects and methods
The post-marketing surveillance (PMS) of losartan was undertaken using the method of prescriptionevent monitoring (PEM). In PEM the exposure data comprise all prescriptions collected throughout England by the Prescription Pricing Authority (PPA). For the drugs being monitored these dispensed prescriptions are transferred electronically (and with care to maintain confidentiality) to the Drug Safety Research Unit (DSRU). This process continues for a period adequate to allow prescriptions to be collected on roughly double the number of patients needed to form the final cohort.
The outcome data are event reports obtained by sending questionnaires (green forms) to the doctors who issued the prescriptions. In the losartan study the prescriptions were written during the period May 1995 to October 1996 and the observation period (for individual subjects, the interval between the first prescription being issued and the green form being sent) was of at least 6 months duration. All green forms are seen the day they are received by the research fellow undertaking the study. All pregnancies, important events, and deaths which could possibly be drug related are carefully followed up by further contact with the doctor who issued the prescription. Additional follow-up is conducted by contact with the NHS authorities and the Office for National Statistics.
The computerisation of the data, the methods of analysis, and the working details of the methodology of PEM have been described in recent publications. [5] [6] [7] [8] PEM provides a numerator and a denominator over a known time frame: it permits, therefore the calculation of the incidence density for each reported event. Thus:
when ID t is the incidence density for an individual event during treatment for period t, N t is the number of reports of the event during treatment for period t, D t is the number of patient-months of treatment for period t and the results are expressed as the number of first reports of the event per 1000 patient-months of treatment. The incidence density estimates can be ranked to provide a clear guide to which events are most frequently reported and this ranking can be compared with other measures, such as the ranked frequency of the reasons for withdrawing the drug for poor tolerance.
The 
Results
Cohort size
A total of 26 303 patients who had commenced treatment with losartan during the collection period were identified from the 81 632 prescriptions provided by the PPA and 15 755 (59.9%) of the 26 303 green form questionnaires sent were returned. Of the green forms returned, 1223 (7.8%) contained no event data. Useful information was therefore available on a cohort of 14 522 patients.
Age and sex
The age was not recorded in 1400 (9.6%) of the patients and the sex was not recorded in 71 (0.5%). In the remaining patients 5834 (40.2%) were males and 8617 (59.3%) were females. The mean age for males was 61.1 ± 11.5 years and the mean age for females was 65.1 ± 12.2 years. Overall the mean age of the cohort was 63.5 ± 12.1 years.
Indications and duration of use
The indications for prescribing losartan were hypertension (63.1%), cardiac failure (7.2%), cough (2.5%), other specified conditions (2.4%), unspecified indications (24.8%). After 6 months of therapy 10 980 (82.5%) of the 13 312 patients for whom it was recorded that treatment was continuing, or that the date of stopping medication was known, were still being prescribed losartan.
Effectiveness
A total of 12 603 (86.8%) of the 14 522 reports included an opinion about the effectiveness of losartan. The GPs considered the drug to have been effective in 10 822 (85.9%) of these cases.
Adverse drug reactions (ADRs)
An event was coded as an ADR if the GP specified on the green form questionnaire that the event was attributable to the drug. A total of 303 ADRs were reported; only 48 (15.8%) of these had been reported to the Committee on Safety of Medicines (CSM). The ten most frequently reported ADRs are shown in Table 1 .
Adverse reactions to other drugs
One hundred and fifty-six (156) ADRs to concomitantly administered drugs were reported in 134 of the losartan-treated patients. These reports were carefully examined to detect drug interactions. There was one possible interaction between digoxin and losartan. In this patient nausea and raised digoxin levels followed the introduction of losartan. Digoxin levels subsequently remained stable following reduction of the dose of the glycoside.
There was also one possible interaction between lithium and losartan. This patient experienced a rise in serum lithium levels following the introduction of losartan. After the dose of this drug was reduced the lithium levels stabilised. The GP reported that 'losartan cleared the excess fluid which is a recognised problem in stabilising lithium levels'.
Reasons for stopping losartan
The 10 most common reasons for stopping losartan are shown in Table 2 . None of the remaining reasons for stopping the drug occurred in more than 0.3% of the cohort.
Incidence densities per 1000 patient-months of exposure
The most frequently reported events are shown, in ranked order, in Table 3 . This table includes all events for which the incidence density in the first month of treatment with losartan (ID 1 ) was equal to or greater than 1 per 1000 patient-months of treatment and the 99% confidence intervals of the difference between the incidence density in the first and subsequent 5 months of treatment (ID 1 -ID 2 ) were significant. Effect of age Table 4 shows the most frequently reported events for which ID 1 -ID 2 (as previously defined) in those aged 76 years and over is significant. It will be noted that the 95% confidence intervals show that the rate ratios comparing patients aged 76 years and over with younger patients are significant for the events: dose increased, dizziness, cough, oedema and nausea/vomiting.
Selected events
The majority of events selected for further study were not adverse reactions but represent aspects of the illnesses being treated. Those reports which were examined but were not considered to be related to losartan are not described further in this paper.
Angioneurotic oedema
There were eight reports of angioneurotic oedema and this was the reason for discontinuation of losartan in four cases. Losartan was considered to be possibly related in four cases. In the remaining four cases it is difficult to assess the causal role of losartan as patients continued with treatment. 
Cough
Cough was the most frequent event reported in the first month of therapy. Two hundred and thirty-six (236) reports of cough occurred in the first 60 days of starting losartan. Early reports of cough may represent 'carry-over' from previous use of ACE inhibitors. A separate study which examined the reporting of cough with losartan and three ACE inhibitors studied by PEM has been conducted. 
Dizziness and related events
Dizziness was the most frequently specified ADR and the third most frequent reason for stopping losartan. Dizziness is a recognised side effect of losartan. 2 There were also rare reports of vertigo, tinnitus and labyrinthitis which resulted in losartan being discontinued. The biological mechanism for these events may be similar to that which causes dizziness. One patient collapsed with dizziness and numbness of the ear within 24 h of increasing the dose of losartan to 100 mg daily. Examination revealed a unilateral sensorineural deafness. One further patient developed whistling and rushing noises in the ear after starting losartan and these noises disappeared after stopping the drug.
Dizziness was reported in 45 patients aged 76 years or older. These reports produced the ID 1 value of 24.1 events per 1000 patient-months of treatment as shown in Table 4 . Of these 45 cases, 12 patients reported dizziness at a dose 25 mg, and 29 patients developed dizziness at a dose of 50 mg. In one patient who was reported to have dizziness the starting dose was 100 mg of losartan. In the remaining three patients who were reported to have dizziness the dose was unknown, as these patients died and their records are unavailable.
Renal failure and electrolyte abnormalities
After follow-up it became clear that many patients with reported renal impairment or electrolyte disorder reported, had pre-existing renal impairment and/or concomitant diuretic medication. As a result, assessment of the possible causal role of losartan in these cases was not possible.
Wheezing and dyspnoea
Nine patients discontinued losartan as a result of wheezing. Losartan was discontinued in a further 32 patients as a result of shortness of breath. It is not known whether the shortness of breath was associated with worsening of cardiac failure as a result of discontinuing previous medication.
Common events
It is notable that dizziness, malaise, lassitude, nausea, cough and headache appear in the top 10 events reported as ADRs (Table 1) , Reasons for Stopping the drug (Table 2 ) and the ranked list of events of the highest incidence density (Table 3) .
Overdose
There were no deliberate overdoses of losartan reported during this study. There was one accidental overdose; this 80-year-old accidentally took losartan 200 mg daily for 2 months (patient misunderstanding) and no ill effects were observed.
Pregnancies and losartan
There were four pregnancies reported during the study. Three mothers took losartan during the first trimester of pregnancy:
(1) Losartan was added and the patient subsequently became pregnant. The pregnancy caused progression of the renal failure and the patient consequently required dialysis. Losartan was discontinued at approximately 8 weeks of gestation. The baby was delivered by casarean section at 29 weeks with growth retardation and died at 9 days. (2) The baby was born prematurely at 30 weeks by caesarean section due to pre-eclampsia and breech presentation. The GP reported that the baby was initially in special care but is now well and no major problems. In this patient losartan had been stopped approximately 6 weeks after the last menstrual period. (3) This 42-year-old mother had an early spon-taneous abortion while taking losartan (6 to 8 weeks gestation). Losartan was discontinued approximately 8 weeks after the last menstrual period.
In the fourth patient, the pregnancy was diagnosed approximately 2 months after stopping losartan. This pregnancy ended in an early spontaneous abortion at 6 weeks of gestation.
Deaths
After follow-up there were 363 deaths, including six cases for which no cause of death could be established. The causes of death are given in Table 5 . None of the deaths were attributed to losartan.
Discussion
The principal strengths of the study This is an observational cohort study in which there was no interference with the decision of the general practitioners regarding which drug to prescribe for their individual patients. The study is, therefore, free of the kind of selection biases which are unavoidable if there is interference with the prescribing decision or if there is a formal process by which patients are either included or excluded from the study.
Prescription-Event Monitoring uses exposure data based on prescriptions which have been dispensed and sent to the PPA for reimbursement. Exposure data in PEM are therefore more reliable than exposure data used in some pharmacosurveillance studies based on prescription data regardless of whether the patient has encashed the prescription.
The study provides information on the 'realworld' use of losartan. The patients are those who would, in everyday clinical practice, be prescribed this drug. They are therefore, likely to cover a greater range of ages and include more patients in need of polypharmacy than the highly selected patients normally included in the clinical studies undertaken for the marketing authorisation application.
The study is of national proportions and is systematic in the sense that the entire cohort for whom prescriptions were available is included and represented the first patients given losartan following its introduction into clinical practice in England.
The study is based upon 'event' monitoring and is, therefore, capable of identifying signals which none of the participating general practitioners suspected to have been due to an adverse drug reaction.
The limitations of the study
Only 15 755 (59.9%) of the 26 303 green forms that were posted were returned. This response rate could conceal possible biases. There has been no method by which the population of patients whose doctors did return the green forms can be compared with the population of patients whose doctors did not return these questionnaires but appropriate validation studies are now in progress. Only one green form was sent for each patient and the response rate is considered satisfactory for general practice postal surveys in general. 10 The response rate is also substantial when compared with the proportion of suspected adverse drug reactions which are reported in spontaneous ADR reporting schemes. 11 In this study 48 (15.8%) of 303 ADRs reported had been reported to the CSM.
General discussion
This study appears to be the largest safety study of losartan so far reported. Losartan appears to be well tolerated with 82.5% of patients still being prescribed the drug after 6 months. The general practitioners reported losartan to have been effective in 85.9% of the 12 603 patients whose GPs recorded an opinion regarding effectiveness.
Hypertension represents the disease being treated (so-called 'confounding by indication'). Cough was frequently reported during this study but may represent a 'carry over' symptom from previous ACEI therapy (particularly if ACEI cough was the reason for switching to losartan). We have previously shown that carry-over effects from previously administered ACE inhibitors account for many of the cases of cough reported during the early days of treatment with losartan. 9 Dizziness was the most frequently reported ADR and is already noted in the Summary of Product Characteristics for losartan. 2 There were also occasional reports of vertigo, labyrinthitis and tinnitus possibly associated with losartan. These events were uncommon but reports were temporally associated with losartan and in some cases symptoms improved after stopping losartan.
There were reports of hyperkalaemia, hypokalaemia and worsening of renal failure with losartan. Assessment of such reports was made more complicated by a history of renal impairment and concomitant cardiovascular drugs. One patient with steadily declining renal function during treatment with losartan was subsequently found to have renal artery stenosis. Hyperkalaemia was reported in 1.5% of patients in preclinical trials. 2 The Summary of Product Characteristics for losartan 2 suggests that serum potassium should be monitored, particularly in the elderly and patients with renal impairment.
Dizziness, malaise, lassitude, nausea, cough and headache were among the more frequently reported ADRs, reasons for withdrawing losartan and events of highest incidence density. Dizziness, cough, oedema and nausea/vomiting were significantly more frequent in patients aged 76 years and over compared with younger patients. The findings suggest that the Data Sheet recommendations regarding starting doses in the elderly are of importance and that care in this regard may avoid some adverse reactions and their consequences.
There were 245 first reports of either asthma, bronchospasm or wheezing. Nine patients discontinued losartan due to wheezing and seven additional patients discontinued losartan due to tight chest. In addition there were 32 reports of dyspnoea which resulted in losartan being discontinued. Some of these cases could be as a result of 556 an exacerbation of cardiac failure but reports also involved patients treated purely for hypertension. Asthma and dyspnoea may be a rare but potentially serious reaction associated with ACEIs. It is possible that similar rare reactions occur in association with the use of losartan. The demonstration ( Table 4 ) that some adverse events occur more frequently in patients aged 76 years and over emphasises the importance of the advice given in the losartan Summary of Product Characteristics regarding starting doses in this age group.
The use of losartan is contra-indicated during pregnancy. Three mothers were exposed to losartan during the first trimester of pregnancy. One pregnancy terminated in a spontaneous abortion. The two remaining pregnancies were both complicated by hypertension. One baby died after extreme prematurity and growth retardation, the second baby survived after being born prematurely. Death certificates were requested for patients who died during the study and for whom there was no clear stated cause of death. None of these deaths were attributed to losartan.
The finding that losartan was well tolerated cannot be ascribed to the failure of PEM to detect 'sig-nals' indicating problems with newly launched medications. A series of such signals have been recently reviewed in the published literature.
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Conclusion
Losartan appears to be well tolerated and GPs frequently rate it as effective. The majority of events reported in this study were not adverse drug reactions and the most frequently reported events were as a result of confounding due to recording of symptoms being treated. There were no unexpected serious adverse events identified in this study. Uncommon events associated with ACEI use such as angioneurotic oedema, hyperkalaemia and bronchospasm may also be associated rarely with losartan.
